Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin.
dapsone
dermatology
dermatopathology
discoid lupus
intravenous immunoglobulin
mycophenolate mofetil
subacute cutaneous lupus erythematosus
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
02
09
2020
revised:
07
10
2020
accepted:
26
10
2020
pubmed:
31
10
2020
medline:
15
5
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%-30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best-known drugs to induce drug-related SCLE. Herein we want to present a 65-year-old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.
Substances chimiques
Immunoglobulins, Intravenous
0
Alendronate
X1J18R4W8P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14477Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115:1409-1415.
Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20:373-385.
Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48:14-19.
Montuno MA, Church AA, Schoch JJ, Andrews ID. Subacute cutaneous lupus erythematosus presenting in twins. Pediatr Dermatol. 2018;35:e128-e131.
Grönhagen C, Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014;5:7-13.
Furzeland J, Malcolm P. Subacute cutaneous lupus erythematosus. J R Army Med Corps. 2017;163:149-151.
Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465-472.
Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107-1111.
Fernandez AP, Kerdel FA. The use of i.v. IG therapy in dermatology. Dermatol Ther. 2007;20:288-305.
De Pità O, Bellucci AM, Ruffelli M, Girardelli CR, Puddu P. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6:415-417.
Goodfield MJD, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004;15:46-50.
Généreau T, Chosidow O, Danel C, Chérin P, Herson S. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol. 1999;135:1124-1125.
Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85:545-547.
Lampropoulos CE, Hughes GRV, Cruz DPD. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol. 2007;26:981-983.
Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011 Dec;65(6):e195-e213. https://doi.org/10.1016/j.jaad.2010.06.017.
Brinkmeier T, Kügler K, Lepoittevin JP, Frosch PJ. Adverse cutaneous drug reaction to alendronate. Contact Dermatitis. 2007;57:123-125.
Schmutz JL, Barbaud A, Trechot P. Alendronate et ulcérations buccales: d'abord bien interroger le patient [alendronate and mouth ulcers: careful interrogation of the patient to start with]. Ann Dermatol Venereol. 2005;132:930.
Lazarov A, Moss K, Plosk N, Cordoba M, Baitelman L. Alendronate-induced lichen planus. Isr Med Assoc J. 2002;4:389-390. 12040836.
Kimura M, Kawada A, Murayama Y, Murayama M. Drug eruption due to alendronate sodium hydrate. Contact Dermatitis. 2003;48:116.
Barrantes-González M, Espona-Quer M, Salas E, Giménez-Arnau AM. Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing. Dermatology. 2014;229:163-168.